Product Images Serevent Diskus
View Photos of Packaging, Labels & Appearance
- Salmeterol chemical structure - sereventdiskus spl graphic 01
- Figure 1 First Treatment Day - sereventdiskus spl graphic 02
- Figure 1 Week 12 - sereventdiskus spl graphic 03
- Figure 2. Cumulative Incidence of Asthma-Related Deaths in the 28-Week Salmeterol Multi-center Asthma Research Trial (SMART), by Duration of Treatment - sereventdiskus spl graphic 04
- Figure 3. Mean Percent Change From Baseline in Postdose FEV1 Integrated Data From 2 Trials of Subjects With Chronic Bronchitis and Airflow Limitation - sereventdiskus spl graphic 05
- Figure 4. Serial 12-Hour FEV1 on the First Day and at Week 12 of Treatment - sereventdiskus spl graphic 06
- Figure A - sereventdiskus spl graphic 07
- Figure B - sereventdiskus spl graphic 08
- Figure C - sereventdiskus spl graphic 09
- Figure D - sereventdiskus spl graphic 10
- Figure E - sereventdiskus spl graphic 11
- Figure F - sereventdiskus spl graphic 12
- Figure G - sereventdiskus spl graphic 13
- Serevent Diskus 50 mcg 60 dose carton - sereventdiskus spl graphic 14
Product Label Images
The following 14 images provide visual information about the product associated with Serevent Diskus NDC 0173-0521 by Glaxosmithkline Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Salmeterol chemical structure - sereventdiskus spl graphic 01
Figure 1 First Treatment Day - sereventdiskus spl graphic 02
Figure 1 Week 12 - sereventdiskus spl graphic 03
Figure 2. Cumulative Incidence of Asthma-Related Deaths in the 28-Week Salmeterol Multi-center Asthma Research Trial (SMART), by Duration of Treatment - sereventdiskus spl graphic 04
Figure 3. Mean Percent Change From Baseline in Postdose FEV1 Integrated Data From 2 Trials of Subjects With Chronic Bronchitis and Airflow Limitation - sereventdiskus spl graphic 05
Description not available. The given text contains some characters which cannot be recognized.*
Figure 4. Serial 12-Hour FEV1 on the First Day and at Week 12 of Treatment - sereventdiskus spl graphic 06
Figure A - sereventdiskus spl graphic 07
Figure B - sereventdiskus spl graphic 08
Figure C - sereventdiskus spl graphic 09
Figure D - sereventdiskus spl graphic 10
Figure E - sereventdiskus spl graphic 11
Figure F - sereventdiskus spl graphic 12
Figure G - sereventdiskus spl graphic 13
Serevent Diskus 50 mcg 60 dose carton - sereventdiskus spl graphic 14
Serevent Diskus is an oral inhalation medication that contains salmeterol xinafoate. Each blister contains 50 mcg of salmeterol base with lactose monohydrate. The NDC code for this medication is 0173-0521-00. Prescribing information for the DISKUS Inhalation Device and dosing information can be found on the package.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
